SAN DIEGO, April 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2016 financial results on Tuesday, May 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
|Date:||Tuesday, May 3, 2016|
|Time:||4:30 p.m. ET|
|Dial-in numbers:||+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)|
|Live webcast:||www.retrophin.com in the "Events & Presentations" section of the "Investors" page|
A replay of the call will be available 7:30 p.m. ET, May 3, 2016 to 7:30 p.m. ET, May 10, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 92067921.
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's marketed products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com